findmyKOL
Clinical trialNCT01737710CompletedInterventional

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment368Dermatitis, Atopic
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • National Jewish Health

    Denver, Colorado, United States

  • Northwestern University

    Chicago, Illinois, United States

  • Boston Children'S Hospital

    Boston, Massachusetts, United States

  • University of Rochester Medical Center

    Rochester, New York, United States

  • Oregon Health & Science University

    Protland, Oregon, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2012
Primary completion
31 May 2013
Completion
31 May 2013
Last update posted
29 Mar 2017
Registered enrollment
368
Registry id
NCT01737710

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.